Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Pharmaceutical GroupSTU:640 -1.89%63 5-Year Yield-on-Cost % is 7.17 as of Jul. 26, 2026, which is 73% above its 10-year median of 4.15. GuruFocus rates STU:640 with a GF Score™ of 63/100 and a GF Value™ of €0.65 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 514 Drug Manufacturers companies, China Resources Pharmaceutical Group ranks better than 83.07% on this metric.
STU:640's 5-Year Yield-on-Cost % is ranked better than 83.07% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.335
vs STU:640: 7.17
China Resources Pharmaceutical Group (STU:640) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
China Resources Pharmaceutical Group 5-Year Yield-on-Cost % Related Terms
STU:640 vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's 5-Year Yield-on-Cost % falls into.
China Resources Pharmaceutical Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
China Resources Pharmaceutical Group (STU:640) has a 5-Year Yield-on-Cost % of 7.17 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on China Resources Pharmaceutical Group and its competitors. This is 73% above median its historical median of 4.15. Over the past decade, China Resources Pharmaceutical Group's 5-Year Yield-on-Cost % has ranged from 1.15 to 8.52. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #87 out of 514 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is China Resources Pharmaceutical Group's 5-Year Yield-on-Cost % too high?
China Resources Pharmaceutical Group's current 5-Year Yield-on-Cost % of 7.17 is 73% above median its 10-year median of 4.15. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 8.52. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.34. China Resources Pharmaceutical Group's value of 7.17 is 207.1% above this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #87 out of 514 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #87 out of 514 companies for 5-Year Yield-on-Cost %. This places China Resources Pharmaceutical Group in the top 17% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.34. China Resources Pharmaceutical Group's value of 7.17 is 207.1% above this benchmark. Historically, China Resources Pharmaceutical Group's own 5-Year Yield-on-Cost % has ranged from 1.15 to 8.52 over the past decade. While the company's 10-year median is 4.15 vs. the industry median of 2.34, China Resources Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.34, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current 5-Year Yield-on-Cost % of 7.17 is 207.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current 5-Year Yield-on-Cost % is 7.17, which is 73% above median its own 10-year median of 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.65, compared to a current price of €0.52 — trading 20% below its estimated fair value. The current 5-Year Yield-on-Cost % is 7.17, which is 73% above median its 10-year median of 4.15 and 207.1% above the Drug Manufacturers industry median of 2.34. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current 5-Year Yield-on-Cost % is 7.17 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.52 is trading 20% below its estimated GF Value™ of €0.65.
GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for STU:640:
5-Year Yield-on-Cost %: 7.17 (73% above median its 10-year median of 4.15)
GF Value™: €0.65 vs. price of €0.52 (20% below fair value)
Industry Position: 207.1% above the Drug Manufacturers median (#87 of 514)
No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score
Get the complete analysis for STU:640
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:640 has been successfully added to your 
